Drug Profile


Alternative Names: Depromel; Fluvoxamine maleate; Luvox; Luvox CR; SME-3110

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Solvay Pharmaceuticals
  • Developer Abbott Laboratories; AbbVie; Jazz Pharmaceuticals plc; Meiji Seika Pharma
  • Class Antidepressants; Oximes; Small molecules
  • Mechanism of Action Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Obsessive-compulsive disorders; Social phobia

Most Recent Events

  • 03 Jul 2017 Registered for Obsessive-compulsive disorders (In adolescents, In children) in Japan (PO) (Meiji Seika Pharma pipeline, August 2017)
  • 01 Aug 2016 AbbVie completes phase-III clinical trials in Obsessive-compulsive disorders (In adolescents; In children) in Japan (PO)
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top